IGF1R and Langer mesomelic dysplasia: Whether ceritinib can be clinically used as an IGF1R inhibitor for patients with LMD is uncertain,43 as it is highly protein-bound in CSF,44 with only ~1.4% (0.012 μM) unbound drug.